Literature DB >> 6109522

Possible embryotoxicity of sulfasalazine.

A Craxi, F Pagliarello.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6109522     DOI: 10.1001/archinte.140.12.1674c

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


× No keyword cloud information.
  8 in total

Review 1.  Fertility and pregnancy in the patient with inflammatory bowel disease.

Authors:  U Mahadevan
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

Review 2.  Pregnancy related issues in inflammatory bowel disease: evidence base and patients' perspective.

Authors:  Christian P Selinger; Rupert Wl Leong; Simon Lal
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

Review 3.  Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy.

Authors:  W Connell; A Miller
Journal:  Drug Saf       Date:  1999-10       Impact factor: 5.606

Review 4.  Inflammatory bowel diseases and management considerations: fertility and pregnancy.

Authors:  Maria Moscandrew; Sunanda Kane
Journal:  Curr Gastroenterol Rep       Date:  2009-10

5.  Effects and treatment of inflammatory bowel disease during pregnancy.

Authors:  Harvinder Brar; Adrienne Einarson
Journal:  Can Fam Physician       Date:  2008-07       Impact factor: 3.275

6.  Maternal drug histories and central nervous system anomalies.

Authors:  K A Winship; D A Cahal; J C Weber; J P Griffin
Journal:  Arch Dis Child       Date:  1984-11       Impact factor: 3.791

Review 7.  Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data.

Authors:  Christina D Chambers; Zuhre N Tutuncu; Diana Johnson; Kenneth L Jones
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

Review 8.  Crohn's disease in women.

Authors:  Ivana Plavšić; Tea Stimac; Goran Hauser
Journal:  Int J Womens Health       Date:  2013-10-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.